Straus M J, Moran R, Muller R E, Wotiz H H
Oncology. 1982;39(4):197-200. doi: 10.1159/000225636.
Tissue from 54 patients with breast cancer was analyzed for estrogen receptor (ER). From 38 patients, tissue from multiple tumor sites was analyzed to determine ER heterogeneity. In 13 patients (34%) both positive and negative ER values were obtained. ER negative (ER-) results were observed more frequently in metastatic lesions. In 28 patients both the ER and [3H]-thymidine labeling index (LI) were measured in the metastatic lesion. [3H]-Thymidine was administered in vivo. There was a positive correlation between ER positivity and low LI. The mean LI of 8 ER positive (ER+) tumors was 3.4 in contrast to a mean LI of 10.0 for 14 ER- tumors (p less than 0.01). LI of 6 mixed ER tumors (ER+/-) was intermediate (mean 5.7). High LI (greater than or equal to 8) was associated with decreased survival regardless of the stage of disease at the time of study. ER with LI may provide an improved basis for treatment selection.
对54例乳腺癌患者的组织进行雌激素受体（ER）分析。从38例患者中，对多个肿瘤部位的组织进行分析以确定ER异质性。在13例患者（34%）中获得了ER阳性和阴性结果。ER阴性（ER-）结果在转移病灶中更频繁地观察到。在28例患者中，对转移病灶同时测量了ER和[3H] - 胸腺嘧啶核苷标记指数（LI）。[3H] - 胸腺嘧啶核苷在体内给药。ER阳性与低LI之间存在正相关。8例ER阳性（ER+）肿瘤的平均LI为3.4，而14例ER-肿瘤的平均LI为10.0（p小于0.01）。6例混合ER肿瘤（ER+/-）的LI处于中间水平（平均5.7）。无论研究时疾病处于何阶段，高LI（大于或等于8）与生存率降低相关。ER与LI可能为治疗选择提供更好的依据。
